blog

Preparing for FDA QMSR: Recommended Actions Based on Your Current Quality System Maturity

Written by Tim Joiner | Jan 20, 2026, 10:45:00 AM

The FDA Quality Management System Regulation (QMSR) took effect on February 2, 2026. It amends 21 CFR Part 820 to incorporate ISO 13485:2016, so FDA inspections of medical device manufacturers now assess compliance against ISO 13485 together with the FDA-specific provisions the rule retains.

What a company needs to do depends on whether it already holds ISO 13485 and MDSAP certification or has only ever worked to the legacy Part 820. There is no grace period beyond the effective date, and firms that are not aligned may be at increased risk during FDA inspections. All manufacturers marketing devices in the U.S. are affected, but the path to compliance looks very different depending on your starting point. Broadly, companies fall into one of two categories:

  • Companies already certified to ISO 13485 and MDSAP
  • Companies operating with a QMS compliant only to legacy 21 CFR 820

Understanding your starting point is critical to defining the right transition strategy. The sections below take each in turn, followed by the expectation that applies to both.

What changes under the FDA QMSR?

Under the QMSR, ISO 13485:2016 becomes the primary quality system framework for FDA compliance, incorporated into 21 CFR Part 820. Part 820 as previously written no longer applies. FDA retains certain FDA-specific requirements where necessary, including complaint handling, reporting, records, and enforcement provisions, so compliance means meeting ISO 13485 and the applicable FDA-specific provisions.

The goal of the change is to reduce regulatory burden, streamline global compliance, and improve consistency across jurisdictions. The rule is published as the final rule in the Federal Register. For how inspectors are applying it, see our analysis of FDA inspections in 2026.

How should ISO 13485 and MDSAP-certified companies prepare for QMSR?

A medical device manufacturer already certified to ISO 13485 and MDSAP is generally well positioned for QMSR, but compliance is not automatic. The work is to confirm and align the existing QMS, with FDA-specific requirements layered on top, rather than to redesign it. A targeted gap assessment and focused remediation is typically sufficient.

FDA expects ISO 13485:2016 to be the core QMS framework, much as MDSAP supplements ISO 13485 with regional requirements. Assumptions can create inspection risk. For the underlying framework, see our ISO 13485 certification consulting services.

Key recommended actions:

  • Confirm ISO 13485 is the primary QMS structure

    • - Procedures, records, and process maps should clearly follow ISO 13485 clause logic.
    • - Avoid parallel or legacy 820-only processes that bypass the ISO framework.
  • Verify that FDA-specific requirements are fully addressed

- Complaint handling and complaint files

- Medical Device Reporting (MDR, the FDA adverse event process) linkages

- Records retention and FDA inspection readiness

- Unique Device Identification (UDI), where applicable

Leverage the MDSAP model

- MDSAP already demonstrates how ISO 13485 requirements are supplemented by regional regulations.

- Treat the FDA QMSR similarly, as a regional overlay rather than a separate QMS.

Ensure risk management is fully integrated

- Risk management should not be limited to design and development.

- Confirm risk-based thinking is embedded across:

  • Purchasing and supplier controls
  • Production and process validation
  • Change management
  • CAPA and post-market surveillance

- Align risk management activities with ISO 14971 and link them clearly to QMS processes.

Update internal audit and management review programs


- Internal audits should explicitly assess QMSR alignment.

- Management review inputs should reflect risk, performance, and regulatory compliance across markets, including the U.S.

Closing gaps early limits disruption and inspection risk.

What does QMSR mean for companies with a QMS compliant only to 21 CFR 820?

A medical device manufacturer whose quality system complies only with legacy 21 CFR Part 820 faces a substantial transformation under the QMSR, not a simple procedure update. The company must adopt ISO 13485:2016 as the foundation of its QMS and incorporate the FDA-specific QMSR requirements into it. Expect a structured implementation effort similar to preparing for initial ISO 13485 certification.

Key recommended actions

Implement ISO 13485:2016 as the core QMS

- Restructure the quality manual and process architecture around ISO 13485 clauses.

- Harmonize procedures to reflect ISO terminology, structure, and intent.

- Address gaps where ISO requirements go beyond legacy 21 CFR 820 expectations.

Incorporate FDA QMSR-specific requirements

- Maintain FDA expectations related to:

  • Complaint handling and MDR (Medical Device Reporting)
  • FDA recordkeeping and inspection access
  • Enforcement and regulatory definitions

- Embed FDA requirements in the ISO framework rather than managing them as standalone processes.

Embed risk management throughout the QMS

- ISO 13485 requires risk-based thinking across all QMS processes.

- Companies transitioning from 21 CFR 820 often need to expand risk management beyond product design.

- Apply risk management systematically to:

  • Supplier qualification and monitoring
  • Process changes and validation
  • Nonconforming product control
  • CAPA prioritization and effectiveness
  • Post-market activities

    Align design controls with ISO and risk management expectations

- Integrate risk management into design and development from concept through the lifecycle.

- Strengthen traceability between risks, design inputs, verification, validation, and post-market feedback.

Update training, audits, and management review

- Train personnel on ISO 13485 concepts and risk-based thinking.

- Redesign internal audit programs to ISO 13485 and QMSR criteria.

- Ensure management review addresses QMS performance, risks, and regulatory obligations together.

Implementing ISO 13485-aligned systems, embedding risk management, and demonstrating maturity takes time, so companies in this group should not wait.

Why does risk management matter across the whole quality system under QMSR?

Risk management integration across the entire quality system is a central expectation under both ISO 13485 and the QMSR. A medical device manufacturer cannot confine risk management to design and development; risk-based thinking has to run through every QMS process. This applies whether a company starts from ISO 13485 and MDSAP certification or from legacy 21 CFR 820.

How can Qserve help with your QMSR transition?

The QMSR is a major regulatory milestone, harmonizing FDA requirements with the internationally recognized QMS standard used worldwide, but the path forward is not the same for every organization. The first step is to assess your current state and plan next steps.

Qserve's US FDA consulting team supports manufacturers with QMSR gap assessments and mock inspections, QMS procedure updates, and internal audit training.

Contact us to discuss your QMSR readiness.